Our Science
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications
Product
HuaTangNing(华堂宁®)
Investor Relations
Investor Center
Corporate Governance
Financial Report
Announcements and Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock Information
Media
Company News
Media Releases
Video
About Us
Company Overview
Company History
Leadership Team
Partner
Portfolio Advisory Board
Senior Scientific Advisory Board
Media Center
Careers
Company Culture
Join Us
Contact Us
中
中
中
Our Science
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications
Product
HuaTangNing(华堂宁®)
Investor Relations
Investor Center
Corporate Governance
Financial Report
Announcements and Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock Information
Media
Company News
Media Releases
Video
About Us
Company Overview
Company History
Leadership Team
Partner
Portfolio Advisory Board
Senior Scientific Advisory Board
Media Center
Careers
Company Culture
Join Us
Contact Us
Our Science
>
Our Science
>
Poster and Presentation
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications
Dorzagliatin as a Glucose Sensitizer Achieved Sustained Glycemic Control in Combination with Metformin in Chinese T2DM Patients in a 52-Week Phase 3 Clinical Trial (DAWN Study)
2021 ADA Poster
Nov 02, 2022
1914
Share
Online link unavailable, presentation available upon request. (BD@huamedicine.com)
Return list
Previous Page
:
Glucokinase Activator Dorzagliatin (HMS5552) Regulates GLP1 Release in T2D Patients and is Synergistic with Sitagliptin and Empagliflozin in Optimizing Beta Cell Function.
Next Page
:
Dorzagliatin as a Glucose Sensitizer Achieved Sustained Glycemic Control in Drug-Naïve T2D Patients in a 52-Week Phase 3 Monotherapy Trial (SEED Study)
About Us
Company Overview
Company History
Leadership Team
Portfolio Advisory Board
Senior Scientific Advisory Board
Partner
Media center
Research & Development
Inovation
Pipeline
Dorzagliatin
mGluR5
Company Publications
Peer Reviewed Publications
Investor Relations
Corporate Governance
Financial Report
Announcements & Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock information
Media
Company News
Media Releases
Video
Careers
Culture
Join Us
Product
HuaTangNing(华堂宁®)
Subscribe Email
Focus Us
Copyright © 2024 Hua Medicine (Shanghai) Co., Ltd. 互联网药品信息服务资格证书编号: (沪)-非经营-2022-0079
沪ICP备14036654号-1
沪公网安备 31011502013809号
Search